XTACY Therapeutics Announces Debt Settlement
XTACY Therapeutics Announces Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2023) - Xtacy Therapeutics Corp. (CSE: XTCY) (FSE: TT5) (OTCQB: GWSFF) (formerly Global Wellness Strategies Inc.) ("the Company") announces that it has agreed to settle an aggregate of CA$118,075 in debt through the issuance of common shares.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年10月5日)-Xtacy Treateutics Corp.(CSE：XTCY)(FSE：TT5)(OTCQB：GWSFF)(前Global Wellness Strategy Inc.)(“The Company”)宣佈已同意通過發行普通股解決總計118,075加元的債務。
The Company has agreed with certain of its creditors to issue an aggregate of 2,361,500 common shares (the "Settlement Shares") to such creditors in exchange for outstanding accounts payable (the "Shares for Debt Transaction") in the aggregate amount of CA$118,075 (the "Debt") owing to certain creditors (the "Creditors"). The Settlement Shares are being issued at a price of $0.05, in accordance with the policies of the Canadian Securities Exchange (the "CSE"). The Company is completing the Shares for Debt Transaction to improve its financial position by reducing its existing liabilities.
本公司已與若干債權人達成協定，將發行合共2,361,500股普通股(“結算股份“)支付給這些債權人，以換取應付未付賬款(”用於債務交易的股票“)總計118,075加元(”債務“)由於某些債權人(”債權人)。根據加拿大證券交易所(The Canada Securities Exchange)的政策，和解股票的發行價為0.05美元。CSE“)。本公司正在完成債務股份交易，以通過減少現有負債來改善其財務狀況。
The securities issued in connection with the Debt Settlement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
根據適用的證券法規，與債務清償相關發行的證券將受四個月的法定持有期外加自發行之日起一天的限制。
Pursuant to the policies of the Canadian Securities Exchange, the Debt Settlement will close five business days from the date of this press release. The Shares for Debt Transaction remains subject to CSE acceptance.
根據加拿大證券交易所的政策，債務和解將自本新聞稿發佈之日起五個工作日結束。債務交易的股份仍須經CSE接納。
About Xtacy Therapeutics Corp.:
關於xtacy治療公司：
Xtacy is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.
Xtacy是一個潛在的創造者，在快速增長的健康消費品市場為高增長的公司提供財務、運營和管理方面的幫助。該公司的重點是全球健康、迷幻劑、真菌學、大麻和CBD、與醫療保健相關的目標公司及其臨床研究和試驗。
For further information, visit website:
欲瞭解更多資訊，請訪問網站：
Or Contact Meris Kott CEO email to kottmeris@gmail.com.
或聯繫Meris Kott首席執行官，電子郵件至kottmeris@gmail.com。
Further information about the Company is available on under the Company's profile.
欲瞭解更多有關本公司的資訊，請訪問：本公司簡介。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。